Newsletter
The Taiwan Intellectual Property Office (TIPO) Releases Taiwanese Patent Information for Novel Coronavirus Clinical Trial Drugs
The World Health Organization (WHO) announced that the novel coronavirus (COVID-19) has reached global pandemic proportions, and as a result, both domestic and international research and development efforts for related diagnosis and treatment methods are in full swing. To promote and protect the results of this research and development, recently the Taiwan Intellectual Property Office (TIPO) has verified the Taiwanese patent database by comparing it with clinical trials related to the novel coronavirus currently registered in the US clinical trial database website (http://clinicaltrials.gov/). On March 13, 2020, the TIPO released current patent information on the coronavirus-related clinical trial drugs in Taiwan to the public for reference.
According to the announcement, current Taiwanese patent information on related clinical trial drugs are as follows:
1. Drugs not registered before TIPO, including small molecule drugs (umifenovir, oseltamivir, ribavirin, chloroquine phosphate, hydroxychloroquine, and thalidomide) and therapeutic proteins (recombinant human interferon α-2b, pegylated interferon α-2b, recombinant human interferon β-1β, eculizumab, mepolizumab, thymosin, and rhACE2).
2. Drugs registered for Taiwanese patents that have claims involving patents of the specific salts, related compound preparation, applications or preparation methods of active ingredients (chemical compounds or antibody molecules), including small molecule drugs (lopinavir/ritonavir, favipiravir, and fingolimod) and therapeutic protein (bevacizumab).
3. Drugs registered for Taiwanese patents with claims that contain core patents of major active ingredients (chemical compounds or antibody molecules), including small molecule drugs (remdesivir, ASC09F or ASC09/ritonavir, darunavir/cobicistat, and danoprevir) and therapeutic proteins (novaferon and anti-PD-1 antibody).
For more details, please refer to the TIPO website ( https://www.tipo.gov.tw/tw/dl-273500-bbecaa7ba4f84ab68107a391086aaac0.html). The public information above will benefit pharmaceutical companies and help with patent planning for the development and research of novel coronavirus diagnosis and treatment methods. It will also help avoid redundant resource allocation and other waste of resources. Therefore, it is well worth the attention of pharmaceutical companies and research organizations.